

شبكة المعلومات الجامعية







شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها على هذه الأفلام قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار في درجة حرارة من ١٥-٥٠ مئوية ورطوبة نسبية من ٢٠-٠٠% To be Kept away from Dust in Dry Cool place of 15-25- c and relative humidity 20-40%



بعض الوثائـــق الإصليــة تالفــة



بالرسالة صفحات لم ترد بالإصل

EVALUATION OF EARLY DETECTION AND MANAGEMENT OF DISSEMINATED INTRAVASCULAR COAGULOPATHY (DIC) IN PATIENTS ADMITTED TO THE PEDIATRIC INTENSIVE CARE UNIT IN ALEXANDRIA UNIVERSITY CHILDREN'S HOSPITAL

15.10

P-ILA

Thesis

Submitted to the Faculty of Medicine
University of Alexandria
In partial fulfillment of the requirements
of the degree of

MASTER OF PEDIATRICS

By

Sama'a Ahmed Essawi MBBCh,Alex

> Department of Pediatrics, Faculty of Medicine University of Alexandria 2002

SUPERVISORS

Prof.Ahmed Amr Abbassy

Professor of Pediatrics
Faculty of Medicine, University of Alexandria.

Care)


Dr.Ahmed Ahmed El- Nawawy

Assistant Professor of Pediatrics
Faculty of Medicine, University of Alexandria

(P)

Dr .Magdy Mamdouh El-Bordiny

Lecturer in Clinical Pathology
Faculty of Medicine, University of Alexandria



CO-SUPERVISOR

Dr.Shahira Barakat

Lecturer in Pediatrics
Faculty of Medicine, University of Alexandria

34 C

ACKNOWLEDGMENT

First of all, thanks to God, the most gracious and the most merciful that I could accomplish this work.

I'm deeply grateful to *Dr.Ahmed Amr Abbassy*, Professor of Pediatrics. His kind help, support and continuous encouragement gave me the need push and advance to this work.

I wish to express my particular thanks to *Dr.Ahmed El-Nawawy*, Assistant Professor of Pediatrics, who suggested this thesis. His vast knowledge in the subject helped in planning this work. Without his keen supervision, continuous discussions and sincere guidance, this work would have never been accomplished. So, I am greatly indebted to him.

My deep thanks are extended to *Dr.Magdy El-Bordiny*, Lecturer in Clinical Pathology. He supervised all the laboratory work, discussed the results and revised the manuscript.

Special thanks to *Dr.Shahira Barakat*, Lecturer in Pediatrics, for her help and support to accomplish this work.

I wish to express my deepest gratitude to all my professors, colleagues, technicians and nursing staff of El-Shatby Children's Hospital especially the PICU nursing staff for their great help and assistance.

.1

To my father and mother....
With all my love.....

CONTENTS

<u>CHAPTER</u>		<u>Page</u>
I	INTRODUCTION	1
II	AIM OF THE WORK	45
Ш	SUBJECTS AND METHODS	46
IV	RESULTS	53
V	DISCUSSION	90
VI	SUMMARY	114
VII	CONCLUSION & RECOMMENDATIONS	119
VIII	REFERENCES	120

APPENDEX PROTOCOL OF THESIS ARABIC SUMMARY

ABBREVIATIONS

APTT Activated partial thromboplastin time.

ARDS Acute respiratory distress syndrome.

ASCO American Society of Clinical Oncology.

AT Antithrombin.

AT III Antithrombin III.

DIC Disseminated intravcular coagulopathy.

EACA Epsilon amino-caproic acid.

FDPs Fibrinogen degradation products.

HMW-K High-molecular-weight kiningen,

Fitzgerald factor

I Fibrinogen

II Prothrombin

III Thromboplastin

INR International Normalization Ratio.

IV Calcium

IX Plasma thromboplastic component (PTC),

Christmas factor, antihemophilic factor B

Ka Kallikrein

MODS Multiple organ dysfunction syndrome.

NIH National Institutes of Health.

PAP Plasmin α₂- Antiplasmin.

PC Protien C.

PICU Pediatric Intensive Care Unit.

PL Platelet phospholipid.

Pre-K Prekallikrein, Fletcher factor.

PRISM Pediatric risk of mortality.

PT Prothrombin time.

TAT Thrombin-Antithrombin complex.

TF Tissue factor.

t-PA Tissue-type plasminogen activator.

TT Thrombin time.

u-PA Urokinase-type plasminogen activator.

V Proaccelerin, labile factor, accelerator globulin

VII Proconvertin, SPCA, stable factor.

VIII Antihemophilic factor (AHF), antihemophilic

factor A, antihemophilic globulin (AHG).

VWF Von Willerand factor.

X Stuart-Prower factor.

XI Plasma thromboplastin antecedent (PTA),

antihemophilic factor C.

XII Hageman factor, glass factor.

XIII Fibrin-stabilizing factor, Laki-Lorand factor.

α₂-AP α₂- Antiplasmin.



Introduction



INTRODUCTION

Hemostasis

I. Definition:

Hemostasis can be defined as that property of the circulation that maintains blood in the fluid state within the blood vessels and prevents excessive blood loss after vascular injury.⁽¹⁾

II. Components of normal hemostasis:

The hemostatic mechanism have several important functions:

- 1. To maintain blood in a fluid state while it remains circulating within the vascular system.
- 2. To arrest bleeding at the site of injury or blood loss by formation of a hemostatic plug.
- 3. To ensure the eventual removal of the plug when healing is complete.

Normal physiology constitutes a delicate balance between these conflicting tendencies and a deficiency or exaggeration of any one may lead to either thrombosis or hemorrhage. There are at least five different components involved: blood vessels, platelets, plasma coagulation factors, their inhibitors and the fibrinolytic system.⁽²⁾




Figure (1): Concept of hemostasis⁽³⁾